Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

Biotechnology

Healthcare
$3.99 -0.81%

-$0.04 today

Market cap
$320.41M
Beta
0.32
P/E (TTM)
-2.0
EPS (TTM)
-$2.14
52W Low $2.78High $6.45

Volume 0.34M

Average 0.34M

AVIR Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Atea Pharmaceuticals, Inc.NASDAQ: AVIR

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital grows in line with its trailing trend

Q1 FY2026 change in working capital of $4.2M (cash outflow) rose 161.7% year over year, ahead of the +159.9% change in trailing-twelve-month change in working capital.

Context

  • Change in working capital increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +161.7% holds above the trailing-twelve-month pace of +159.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.2M-122.0% QoQ
Last fiscal yearDec 2025
$16.48M+320.5% YoY
LTMMar 2026
$13.89M+159.9% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+161.7%——
1 year+320.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
16.48M USD
Year-over-year change
+320.5%

Change in Working Capital vs competitors

How AVIR compares with its peers on the latest reported figures

  • AVIR's LTM Mar 2026 change in working capital of $13.89M is the smallest of the 5 companies compared; the peer median is $53.98M.
  • Its year-over-year change of +159.9% is the highest of 5, against a peer median of -144.2%.
AVIR Competitors Peer median
Change in Working Capital for AVIR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABUSArbutus Biopharma CorporationLTM Mar 2026$194M -3761.0%—101.3%
VIRVir Biotechnology, Inc.LTM Mar 2026$71.19M -394.2%—108.7%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$36.78M +105.8%+162.3%51.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$34.76M +146.8%+80.5%50.2%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$13.89M +159.9%——
Peer median (excluding AVIR) $53.98M-144.2%+121.4%76.5%

Competitors are the stored peer set for AVIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income121.19M(115.91M)(135.96M)(168.39M)(158.35M)
Depreciation & Amortization29K260K416K416K416K
Deferred Income Tax(29.39M)0(48.56M)0(6.36M)
Stock-Based Compensation39.62M46.72M49.43M51.77M20.72M
Change in Working Capital(247.85M)(46.59M)16.16M(7.48M)16.48M
Accounts Receivables00000
Inventory00000
Accounts Payables10.29M(1.98M)1.7M206K8.49M
Other Working Capital(258.13M)(44.6M)14.46M(7.68M)8M
Other Non-Cash Items29.39M(5.47M)33.11M(11.82M)(4.94M)
Operating Cash Flow(87.01M)(120.98M)(85.4M)(135.5M)(132.03M)
Capital Expenditures(4K)(1.94M)000
Acquisitions (Net)0453.47K000
Purchases of Investments0(545.35M)(562.36M)(461.18M)(281.94M)
Sales of Investments091.89M602.67M517.28M470.73M
Other Investing Activities0(453.47K)000
Investing Cash Flow(4K)(455.41M)40.3M56.11M188.79M
Debt Repayment00000
Common Stock Issued1.47M230K257K267K259K
Common Stock Repurchased0000(25.52M)
Dividends Paid00000
Other Financing Activities0140K00(485K)
Financing Cash Flow1.47M370K257K267K(25.75M)
Effect of Forex Changes00000
Net Change in Cash(85.54M)(576.02M)(44.84M)(79.13M)31.02M
Free Cash Flow(87.01M)(122.93M)(85.4M)(135.5M)(132.03M)

Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

Intrinsic Alpha fair value

Locked

Current Price

$3.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.